Multiple Myeloma Hub

57 Afleveringen

1. How can we use the microbiome to improve cancer immunotherapy and alleviate side effect such as graft-versus-host-disease

   Gepubliceerd: 8-7-2020
2. Melphalan flufenamide (melflufen) + novel agents for RRMM

   Gepubliceerd: 8-7-2020
3. Isatuximab plus KRd for high-risk NDMM

   Gepubliceerd: 24-6-2020
4. Novel approaches in multiple myeloma: what is unique about CELMoDs?

   Gepubliceerd: 24-6-2020
5. Hot topics in MM: quadruplets and anti-BCMA therapy

   Gepubliceerd: 24-6-2020
6. Genomics of high-risk myeloma

   Gepubliceerd: 23-6-2020
7. The association between the diversity of the oral microbiome and PFS

   Gepubliceerd: 22-6-2020
8. Novel approaches in multiple myeloma: BFCR4350A

   Gepubliceerd: 18-6-2020
9. Update from CARTITUDE-1 | What's new since ASH?

   Gepubliceerd: 8-6-2020
10. Novel approaches in multiple myeloma: TAK-079

    Gepubliceerd: 4-6-2020
11. Should we use KRd or VRd for patients with NDMM?

    Gepubliceerd: 4-6-2020
12. What is the optimal treatment for bone lesions, including patients with renal insufficiency?

    Gepubliceerd: 3-6-2020
13. Recent advances in our understanding of myeloma progression

    Gepubliceerd: 2-6-2020
14. Quadruplet combinations in transplant-ineligible NDMM: isatuximab + Vd + cyclo or len

    Gepubliceerd: 1-6-2020
15. How I treat elderly patients with NDMM

    Gepubliceerd: 28-5-2020
16. Understanding resistance mechanisms to current standard of care and how to overcome them

    Gepubliceerd: 19-5-2020
17. What is plasma cell leukemia and what are the latest advances in treatment?

    Gepubliceerd: 15-5-2020